logo

Royality Med Pharmaceuticals Group

Royality Med's mission is to fast-track the early stage of drug discovery using our predictive models of the human brain for therapeutic success. Many neurodevelopmental diseases do not have treatments due to a lack of a-priori knowledge of the underlying biology. Royality Med's technology is able to model these diseases to help enable the discovery of new targets and drugs, de-risking the current failure-prone cumbersome approach.
For inquiries, please contact us at
E-mail: info@royalitymedgrp.com
mobile-logo
 

Pipeline & Products

The Journey Toward Regenerative Medicine Has Already Begun:



At Royality Med Pharmaceuticals Group, we recognize that every field is unique, and farmers require solutions that work together to tackle their challenges and maximize yields. That’s why we develop innovations designed to be adaptable to each grower’s needs, functioning as integrated systems—from high-performing seeds at planting to crop protection products and digital tools used daily to manage their fields.

Backed by industry-leading investment in research and development and a dedication to delivering digitally empowered tools tailored to growers worldwide, we are positioned to bring next-generation technologies and solutions to fruition.

Our commitment to regenerative agriculture drives our innovation agenda. Our R&D priorities are shaped by farmers’ demands for integrated, effective solutions that help address crop threats, boost productivity, minimize environmental impact, and optimize farm performance globally.





Biological Breakthroughs:



Not long ago, biological options were primarily associated with microbials; however, the biologicals industry is now rapidly expanding into diverse areas. This growth includes innovative nature-derived biocontrol and biostimulant solutions such as pheromone products, botanicals, plant extracts, and even advances in synthetic biology.

Biologicals provide new avenues for solutions, including the use of synthetic biology to introduce nitrogen-fixing microbes to key food security crops like corn, wheat, and rice—crops that currently do not fix nitrogen from the air but could potentially do so in the future.

Royality Med Pharmaceuticals Group (RMPG) is at the forefront of developing and expanding the biologics segment as the preferred partner for R&D and commercialization. Leveraging our trusted brand, regulatory expertise, and global market reach, we accelerate bringing innovative products to market. Partners who might otherwise reach only thousands of growers can expand their impact to millions through collaboration with Royality Med Pharmaceuticals Group.




Digital and Carbon Frontiers:



Digital tools and data have been revolutionizing agriculture for decades. Early advancements in analytics and software, initially applied in labs and greenhouses, enabled us to uncover genetic markers hidden within vast datasets. Subsequently, innovative digital tools like FieldView made their way onto farms, empowering growers to make informed decisions using data far beyond what is visible to the naked eye.

Now, a new frontier is emerging. What began in research labs as a platform for developing best-in-class seeds and traits, and then expanded to providing actionable insights on farms, is evolving once again—extending beyond the farm itself and into the entire value chain.

Agriculture is a complex industry, and over the past 20+ years, we have worked to create and standardize data. Today, in this era of digitization, the focus is on generating and utilizing valuable data to offer guidance, build trust, and enable growers to actively participate and benefit within the value chain.



A Customer Driven Precision Breeding Pipeline:



Precision breeding will speed up the creation of new products, making them much more customized to meet our customers’ specific fields and needs.

We’re leveraging these tools not only to measure customer preferences but also to integrate those insights with multi-layered data and an in-depth genomic understanding of our germplasm. This allows us to predict the desirable traits for the next generation of corn hybrids.

By using precision breeding, we aim to shorten one breeding cycle from 6 years to just 4 months—more than doubling our genetic improvement rate by 2030. This marks one of the most groundbreaking advancements in the history of plant breeding.



Transformative Traits



Royality Med Pharmaceuticals Group’s Crop Science division is the unrivaled leader in plant biotechnology. We have introduced more biotech traits than any other company, empowering farmers to cultivate crops such as corn, soybeans, cotton, and canola with transformative capabilities across approximately 300 million acres annually.

By leveraging expertise in four core technologies – gene, protein, RNA, and genome – Royality Med Pharmaceuticals Group continuously refreshes and enhances our trait portfolio and biotech pipeline, including developing the largest multi-gene stacks available to growers.




I would like to learn about Royality Med’s Pharmaceuticals Group discoveries to treat genetic diseases.


YES, TELL ME MORE